Helix BioMedix, Inc.

Helix BioMedix, Inc. is a privately held biotechnology company based in Bothell, Washington, focused on the discovery and early-stage development of peptide-based therapeutics for dermatology and skin health. According to its official website, the company describes itself as merging science and care to create innovative dermatologic treatments, transforming skin health with precision, safety and purpose. Its stated mission is to transform peptide science into life-enhancing innovations built on safety, efficacy and scientific integrity. The company's lead drug development program targets Xeroderma Pigmentosum (XP), a rare genetic disorder that impairs the skin's ability to repair UV-induced damage. Helix BioMedix is advancing preclinical research for a potential treatment for XP, emphasizing rigorous science and targeted innovation to bring forward potential therapeutic candidates. Beyond its therapeutic work, the company maintains a legacy peptide platform that supports select applications in personal care and related markets. Helix BioMedix has decades of expertise in peptide discovery and development. Its management team is led by Robin L. Carmichael, who serves as President, Chief Executive Officer and Chairperson of the Board. Carmichael was appointed President and CEO in July 2017, having previously served as President from February 2015 and Chief Operating Officer since January 2011; she joined the company in October 2007 as vice president of marketing and business development. R. Stephen Beatty, a long-serving board member and former CEO, previously served as Chairman of the Board from January 2020 to September 2024 and as Executive Chairman from February 2015 to December 2019. The company is headquartered at 19125 Northcreek Parkway, Suite 120, Bothell, WA 98011, with a mailing address of PO Box 1748, Bothell, WA 98041. It operates as a privately held company focused on long-term value creation through responsible research and transparent governance, and maintains an investor relations section on its website for corporate updates.

Helix BioMedix, Inc. is a biotechnology company headquartered in Bothell, Washington, with a history in peptide discovery and development spanning decades. The company describes itself as having decades of expertise in peptide discovery and development, and it has built a proprietary peptide technology platform that it applies to dermatology and skin health. R. Stephen Beatty served as the company's Chief Executive Officer and a member of its board of directors from May 1999. He later served as Executive Chairman of the Board from February 2015 to December 2019, and as Chairman of the Board from January 2020 to September 2024. Robin L. Carmichael joined Helix BioMedix in October 2007 as vice president of marketing and business development. She was appointed Chief Operating Officer in January 2011, became a member of the board of directors in February 2013, and was appointed President in February 2015. In July 2017 she was appointed President and Chief Executive Officer, and in September 2024 she was appointed Chairperson of the Board. Over time, the company has maintained a legacy peptide platform supporting select applications in personal care and related markets, while shifting its therapeutic focus toward rare and underserved dermatologic conditions. Its current lead program is a preclinical research effort targeting Xeroderma Pigmentosum (XP), a rare genetic disorder caused by defective DNA repair mechanisms that impairs the skin's ability to repair UV-induced damage. The company emphasizes early-stage research and discovery in dermatological and genetic disorders, with a stated emphasis on rigorous science and targeted innovation to bring forward potential therapeutic candidates. As of its official website, Helix BioMedix is a privately held biotechnology company focused on long-term value creation through responsible research and transparent governance. It maintains an investor relations section for corporate updates and information.

• 2024

  Robin L. Carmichael appointed Chairperson of the Board (September 2024), succeeding R. Stephen Beatty.

• 2020

  R. Stephen Beatty becomes Chairman of the Board (January 2020).

• 2017

  Robin L. Carmichael appointed President and Chief Executive Officer (July 2017).

• 2015

  Robin L. Carmichael appointed President (February 2015); R. Stephen Beatty becomes Executive Chairman (February 2015).

• 2013

  Robin L. Carmichael becomes a member of the board of directors (February 2013).

• 2011

  Robin L. Carmichael appointed Chief Operating Officer (January 2011).

• 2007

  Robin L. Carmichael joins Helix BioMedix as vice president of marketing and business development (October 2007).

• 1999

  R. Stephen Beatty begins serving as Chief Executive Officer and board member (May 1999).

A privately held biotechnology company focused on peptide-based dermatologic innovation, with a lead preclinical program in a rare genetic skin disorder and a legacy peptide platform for personal care.

• Preclinical program targeting Xeroderma Pigmentosum (XP)

  Early-stage research and discovery for a potential treatment targeting XP, a rare genetic disorder that impairs the skin's ability to repair UV-induced damage.

• Legacy peptide platform

  Supports select applications in personal care and related markets.

1. 1Helix Biomedix, Inc. - Helix BioMedix Inchelixbiomedix.com
2. 2About - Helix BioMedix Inchelixbiomedix.com
3. 3Management Team - Helix BioMedix Inchelixbiomedix.com
4. 4Board of Directors - Helix BioMedix Inchelixbiomedix.com
5. 5Helix Biomedix (United States) - Wikidatawikidata.org